Adjust subsequent doses according to patient tolerance. Pretreatment platelet count and performance status are important prognostic factors for severity of myelosuppression in previous treated patients. Frequently monitor peripheral blood counts until recovery is achieved. Generally, do not repeat single intermittent courses until WBC, neutrophil, and platelet counts recover. Carefully monitor blood counts of renally impaired patients between courses.
Creatinine clearance is most sensitive measure of kidney function in carboplatin-treated patients.
In patients who previously received cisplatin for advanced ovarian carcinoma, those whose disease progressed during therapy may have a decreased response rate to carboplatin. Contraindicated in patients with a history of allergic reactions to cisplatin or other platinum-containing compounds or mannitol. There is an increased risk of allergic reactions, including anaphylaxis, in patients previously exposed to platinum therapy. Contraindicated in patients with severe bone marrow depression or significant bleeding. Patients with poor performance status have a higher incidence of severe leukopenia and thrombocytopenia.